- Treatment of Acute Myeloid Leukemia with 20-30% blasts in patients who are not eligible for Haemopoietic stem cell transplant
- Intermediate-2 and High-risk Myelodysplastic syndrome (MDS)

Azafab 100mg Injection
| MRP | : |
|
| Price | : | ₹2,400.00 |
| You Save | : | ₹1,316.59 (35.42%) |
1 Vial(s)
Azafab 100mg Injection is utilized for the treatment of adults diagnosed with Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) when they are deemed ineligible for a stem cell transplant.
In the case of Myelodysplastic Syndrome, the bone marrow fails to generate healthy blood cells due to its impaired function. Acute Myeloid Leukemia, on the other hand, is a form of bone marrow cancer characterized by the release of improperly developed blood cells into the bloodstream.